Similarly, ACM derived from OGJ patients with early-stage and late-stage tumours significantly increased the frequency of central memory CD8+ T cells compared with untreated cells (untrx: 4.86 ± 0.6 vs. early-stage: 7.43 ± 0.8%, p = 0.05, late-stage: 9.12 ± 1.8%, p = 0.04) (Fig. 1B). The gene discussed is CD8A; the disease is neoplasm.